These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

899 related articles for article (PubMed ID: 27898234)

  • 21. Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
    Uluer AZ; MacGregor G; Azevedo P; Indihar V; Keating C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Rubenstein RC; Taylor-Cousar JL; Tullis E; Yonker LM; Chu C; Lam AP; Nair N; Sosnay PR; Tian S; Van Goor F; Viswanathan L; Waltz D; Wang LT; Xi Y; Billings J; Horsley A; ;
    Lancet Respir Med; 2023 Jun; 11(6):550-562. PubMed ID: 36842446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment.
    Ejiofor LCK; Mathiesen IHM; Jensen-Fangel S; Olesen HV; Skov M; Philipsen LKD; Pedersen CL; Pressler T
    Pediatr Pulmonol; 2020 Dec; 55(12):3364-3370. PubMed ID: 32897653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
    Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M;
    Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.
    Burgel PR; Munck A; Durieu I; Chiron R; Mely L; Prevotat A; Murris-Espin M; Porzio M; Abely M; Reix P; Marguet C; Macey J; Sermet-Gaudelus I; Corvol H; Bui S; Lemonnier L; Dehillotte C; Da Silva J; Paillasseur JL; Hubert D;
    Am J Respir Crit Care Med; 2020 Jan; 201(2):188-197. PubMed ID: 31601120
    [No Abstract]   [Full Text] [Related]  

  • 26. Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.
    Deeks ED
    Drugs; 2016 Aug; 76(12):1191-201. PubMed ID: 27394157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
    Taylor-Cousar JL; Munck A; McKone EF; van der Ent CK; Moeller A; Simard C; Wang LT; Ingenito EP; McKee C; Lu Y; Lekstrom-Himes J; Elborn JS
    N Engl J Med; 2017 Nov; 377(21):2013-2023. PubMed ID: 29099344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.
    Hoppe JE; Chilvers M; Ratjen F; McNamara JJ; Owen CA; Tian S; Zahigian R; Cornell AG; McColley SA
    Lancet Respir Med; 2021 Sep; 9(9):977-988. PubMed ID: 33965000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results.
    Murer C; Huber LC; Kurowski T; Hirt A; Robinson CA; Bürgi U; Benden C
    Swiss Med Wkly; 2018; 148():w14593. PubMed ID: 29451946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for
    Rayment JH; Asfour F; Rosenfeld M; Higgins M; Liu L; Mascia M; Paz-Diaz H; Tian S; Zahigian R; McColley SA
    Am J Respir Crit Care Med; 2022 Nov; 206(10):1239-1247. PubMed ID: 35771568
    [No Abstract]   [Full Text] [Related]  

  • 32. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
    Rowe SM; Daines C; Ringshausen FC; Kerem E; Wilson J; Tullis E; Nair N; Simard C; Han L; Ingenito EP; McKee C; Lekstrom-Himes J; Davies JC
    N Engl J Med; 2017 Nov; 377(21):2024-2035. PubMed ID: 29099333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial.
    Sagel SD; Khan U; Heltshe SL; Clancy JP; Borowitz D; Gelfond D; Donaldson SH; Moran A; Ratjen F; VanDalfsen JM; Rowe SM
    Ann Am Thorac Soc; 2021 Jan; 18(1):75-83. PubMed ID: 32644818
    [No Abstract]   [Full Text] [Related]  

  • 35. Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation.
    Berkers G; van der Meer R; Heijerman H; Beekman JM; Boj SF; Vries RGJ; van Mourik P; Doyle JR; Audhya P; Yuan ZJ; Kinnman N; van der Ent CK
    J Cyst Fibros; 2021 Sep; 20(5):761-767. PubMed ID: 33249003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
    Bulloch MN; Hanna C; Giovane R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Cystic Fibrosis Patients Homozygous for
    Favia M; Gallo C; Guerra L; De Venuto D; Diana A; Polizzi AM; Montemurro P; Mariggiò MA; Leonetti G; Manca A; Casavola V; Conese M
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
    McKone EF; DiMango EA; Sutharsan S; Barto TL; Campbell D; Ahluwalia N; Higgins M; Owen CA; Tullis E
    J Cyst Fibros; 2021 Mar; 20(2):234-242. PubMed ID: 33339768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.